OncoSil Medical

OncoSil Medical Limited is a publicly traded medical device company based in Macquarie Park, Sydney, Australia, with operations in Europe and the Asia Pacific region. Founded in 2005, the company focuses on developing and commercializing localized radiation therapy devices for treating pancreatic and distal cholangiocarcinoma cancers. The flagship product, OncoSil™, is a single-use brachytherapy device that delivers targeted intratumoural radiation therapy using Phosphorous-32 (32P). It is designed to be used alongside gemcitabine-based chemotherapy for patients with locally advanced pancreatic cancer. OncoSil™ is implanted directly into the tumor, aiming to enhance treatment efficacy while reducing damage to surrounding healthy tissue. OncoSil Medical has made significant progress, including completing patient recruitment for clinical trials and receiving MDR approval for broader market access in Europe. The company is dedicated to transparency and governance, regularly updating shareholders on its developments. Its primary customers are healthcare providers and hospitals specializing in oncology, particularly those focused on advanced treatment options for pancreatic cancer.

• Employees 28